Pharmacokinetic parameters of SQdFdC, dFdC or dFdCNA, and dFdU in mice treated i.v. with either SQdFdC nanoassemblies (15 mg/kg mol Eq of dFdC) or dFdC (15 mg/kg) in DBA/2 female mice
Parameter | SQdFdC-Treated Mice (15 mg/kg Equivalent in Gemcitabine, n = 4) | dFdCcon-Treated Mice (15 mg/kg, n = 4) | ||||||
|---|---|---|---|---|---|---|---|---|
| SQdFdC | dFdCNA | dFdU | dFdC | dFdU | ||||
| t1/2 (h) | 8.6 | 6.3 | 10.5 | 1.6 | 8.5 | |||
| C0 (ng/ml) | 120,122 | 38,355 | ||||||
| Cmax (ng/ml) | 6627 | 10,756 | 10,375 | |||||
| Tmax (h) | 0.017 | 2.0 | 0.5 | |||||
| Y0-∞ (ng/h/ml) | 44,178 | 6043 | 112,701 | 5413 | 54,243 | |||
| Cl (ml/h/kg) | 831a | 2481b | 2770 | |||||
| Vss (ml/kg) | 1740a | 7344b | 1074 | |||||
| MRT (h) | 2.1 | 3.0 | 15.3 | 0.4 | 8.7 | |||
t1/2 (hours), terminal elimination half-life; C0 (nanograms per milliliter), extrapolated plasma concentration at t = 0; Cmax (nanograms per milliliter), maximum observed plasma concentration; Tmax (hours), time to reach the Cmax; Cl (milliliters per hour per kilogram), total body plasma clearance; Vss, volume of distribution at steady-state (milliliters per kilogram); MRT, mean residence time
↵ a Cl and Vss values of SQdFdC were calculated considering a dose of 36.6 mg/kg SQdFdC
↵ b Cl and Vss of dFdCNA were calculated using a dose of 15 mg/kg dFdC and i.v. route